The 2022 American College of Cardiology (ACC)/American Heart Association (AHA)/Heart Failure Society of America Guidelines for the Management of Heart Failure: (Failure, 2021): SGLT-2 inhibitors as the first choice for the therapy of heart failure, including dapagliflozin. The gene discussed is SLC5A2; the disease is heart failure.